Background: This study was designed to examine basal and stress-induced levels of the
neuroactive progesterone metabolite, allopregnanolone, in women with premenstrual …

OBJECTIVE: To evaluate the anxiolytic 3α-5α-reduced progesterone metabolite
allopregnanolone in the luteal phase of the menstrual cycle in women with premenstrual …

Allopregnanolone is a neuroactive metabolite of progesterone and a barbiturate-like
modulator of central γ-aminobutyric acid A receptors that modify a range of behaviors …

Objective To evaluate basal allopregnanolone and progesterone in both phases of the
menstrual cycle in women suffering from premenstrual syndrome (PMS) and their response …

Twenty-six women meeting DSM criteria for premenstrual dysphoric disorder (PMDD) and
39 non-PMDD controls were tested for allopregnanolone (ALLO) responses to mental stress …

Rationale In premenstrual dysphoric disorder (PMDD), a condition that afflicts 3–8% of
women in fertile ages, the cyclic recurrence of debilitating mood symptoms is restricted to the …

Abstract Changes in neurosteroid levels during the luteal phase of the menstrual cycle may
precipitate affective symptoms. To test this hypothesis, we stabilized neurosteroid levels by …

Rationale Allopregnanolone effects on mood in postmenopausal women are unclear thus
far. Objectives Allopregnanolone is a neuroactive steroid with contradictory effects …

Objective: To compare severity of negative mood and physical symptoms between women
with different progesterone, allopregnanolone, and pregnanolone plasma concentrations …

Certain women experience negative mood symptoms as a result of progesterone during the
luteal phase of the menstrual cycle, progestagens in hormonal contraceptives, or the …